MMJ Group Holding

Hallo Ariva Gemeinde,

zeit für ein aktuelles Forum für MMJ Group Holding (ehemalige MMJ PhytoTech). Das Web zeigt folgendes an.

MMJ Group Holdings Limited (MMJ) is an Australian-listed company whose core business is holding minority investments along the cannabis value-chain in Australia, Canada and Europe.
Hompage:
https://www.mmjgh.com.au/...n%20Australia%2C%20Canada%20and%20Europe.

2 börsennotierte Beteiligungen (WeedMD,Harvest One) aus Canada haben gerade gute News gebracht.

Quelle:
https://www.globenewswire.com/news-release/2021/...ower-Products.html
WeedMD’s Saturday Cannabis Vaporizers Debut as the Top Seller in Ontario and Color Cannabis Brand Launches 15 gram Dried Flower Products
Quelle:
https://finance.yahoo.com/news/...-livrelief-cbd-cream-130000684.html
Harvest One's LivRelief CBD Cream is the Number One Selling SKU for Cannabis-Infused Topicals in Ontario

Ich bin Investiert. Keine Beratung oder Handlungsempfehlungen. DYOR

 

MMJ Global hält 12% an Embark aus Canada
Quelle: https://www.embarkhealthinc.com/  

Heute wieder sattes grün bei MMJ's Beteiligungen.
Harvest One +41% und WeedMD +27%.
Und die Australier träumen von Schafen.  

MMJ holds a CAD$2.5 million convertible note, 24% shareholding, and rights to make further future investments in Sequoya.
Quelle: https://www.proactiveinvestors.com.au/companies/...europe-937402.html

Homepage: https://sequoyaglobal.com/de/
Homepage: https://www.mmjgh.com.au/2020/02/05/...receives-eu-gmp-certification/


 

Sehe hier Limit setzen und Heimatbörse Australien als größtes Problem.

Kurzes Nickerchen und dann geht's in Australien weiter.  

User Starkode schreibt:
55 + 17 millions shares (assuming the warrant are exercised) that is 72m x 60c = $42 million just with HVT more than 50% of our market cap
MMJ would have to reach 30c today ....?

Ich liebe diese Australier, alles Kopfstandträumer.  

Danke Ariva. Webseite ist jetzt aktualisiert.
Ob die Amis das merken ? :-(


 

Kommt schon Amis. Die Bude ist mit den Beteiligungen mindestens 2Mrd.  wert. Kauft.  

23/03/2021
MMJ change of registered office and principal place of business address
Homepage: https://www.mmjgh.com.au/2021/03/23/...pal-place-of-business-address/
Suite 5706, Level 57, MLC Centre
19-29 Martin Place SYDNEY
NSW 2000 AUSTRALIA

Tel: 02 9236 7334
Facsimile: 02 8080 8315

Quelle: https://en.m.wikipedia.org/wiki/MLC_Centre  

Embark Health IPO bis Ende Juni21

14/04/2021
Embark Health Inc. General Business Update to Shareholders
Embark Health Inc. (“Embark” or “the Company”) is pleased to report on its progress for first 11 weeks of 2021 as Embark continues to deliver its strategic business development priorities on several fronts.
Quelle: https://www.mmjgh.com.au/2021/04/14/...siness-update-to-shareholders/

...Embark continues to work toward a public listing in 2021. On 11 March 2021Embark management decided to pursue a direct listing rather than the Reverse Take Over (RTO) of Mesa Exploration.  

Quelle: https://finance.yahoo.com/news/...nce-proposed-reverse-114500856.html
Mesa and CoinSmart Announce Proposed Reverse Takeover Transaction and Concurrent Private Placement of CoinSmart

...Therefore, Embark and Mesa Exploration mutually agreed to terminate without any break fees owed. Embark aims to complete the public listing process by the end of June 2021.  

Da ist sicher jemand traurig dem Geld hinterherschauen zu müssen.
 

Danke für die Werbung. Der Gewinn liegt im EK und nicht im Treadbeginn.  

müssen tue Ich garnix. Mein Kursziel bis hier ist das
Vor-Corona-Niveau. Aber was sag ich, mit Kursen kennen Sie sich besser aus.  

"kauft, wenn alle ängstlich sind und die größten Schreier am Markt verkaufen rufen :)"

iDonk  

MMJ Group Holdings Ltd (ASX:MMJ, OTC:MMJJF) has completed an investment of A$1 million in the unlisted Valo Therapeutics Oy, as part of a total pre-initial public offering (IPO) equity financing of around US$13 million.

The Finland-based immunotherapy company that is developing antigen-coated oncolytic viruses and vaccine vectors as therapeutic vaccines against cancer and infectious diseases, is preparing for an IPO in 2022.

MMJ's investment was made from the company existing cash reserves.

Investment strategy
MMJ Group chair Peter Wall said: “The investment in Valo demonstrates MMJ’s expertise to secure a private negotiated investment in unlisted businesses, which are not generally available to Australian retail and institutional investors.

“Valo represents the continued deployment of funds in accordance with its investment strategy following the broadening of MMJ’s investment mandate in 2020.”

Validate PeptiCRADd platform
Valo Therapeutics CEO Paul Higham said: ”This successful financing is yet another significant milestone as we further validate our PeptiCRAd platform and now take the important step into the first clinical study.

“In addition, the financing will allow us to further validate our other oncology and infectious disease platforms and our pan Coronavirus T-cell vaccine.”

Valo Therapeutics successfully raised €11 million in an oversubscribed pre-IPO funding round, with participation coming from existing investors, Freeman Road, and new investors, MMJ.

The total raised to date is now over €22 million.

Valo Therapeutics
Valo Tx’s lead platform, PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus), was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki.

It turns oncolytic adenoviruses into targeted, tissue-specific cancer vaccines without the need to develop and manufacture multiple genetically modified viruses.

The company is seeking to fund the finalisation of preparations and initiation of a Phase 1 clinical study PeptiCRAd-1, in addition to the continued development of its anti-infectives platforms including PeptiBAC and PeptiVAX.

Quelle: https://www.mmjgh.com.au/2021/11/16/...ts-aud1m-in-valo-therapeutics/

Quelle: https://www.valotx.com/articles